However, despite the lack of robust genome-wide methylation responses and in stark contrast to the gene expression studies, ASMCs from the asthma cases had fewer differentially methylated probes (DMPs) in response to the combined treatment of IL-13+IL-17A, with 0 DMPs observed in the cases and 260 DMPs observed in controls at an FDR < 5%. The gene discussed is IL17A; the disease is asthma.